August 2014

Study results indicate BAX326 shows potential and is an efficacious and safe alternative treatment for patients with hemophilia B.

Prophylactic treatment for hemophilia B requires fewer injections than current options.

Fewer injections and longer duration of treatment effect should lead to significant improvements in quality of life.

Bayer Healthcare and Dimension Therapeutics recently announced a partnership to advance innovative treatment options for patients with hemophilia A.

Patients on FVIII therapies may develop antibodies that diminish treatment efficacy, may not be able to handle frequent dosing schedules, and may not be able to afford the cost of treatment.

A drug that was approved less than 1 year ago to help with the prevention and treatment of bleeding in patients with hemophilia A may not have the desired effect, according to a recent study.